Is Type 2 Diabetes a Modifiable Risk Factor for the Evolution and Progression of Heart Failure With a Preserved Ejection Fraction?
Key result
Targeting adiposity rather than hyperglycemia modifies HFpEF risk in patients with diabetes.
Why the study?
Does targeting adiposity rather than hyperglycemia reduce the risk or progression of HFpEF in patients with Type 2 diabetes?
Population
Patients with Type 2 diabetes and heart failure with preserved ejection fraction (HFpEF)
Comparison
Treatments directed toward adiposity vs Treatments directed toward hyperglycemia
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Type 2 diabetes is a modifiable risk factor for HFpEF only when treatments target the associated excess adiposity rather than just hyperglycemia.
Key Points
- Diabetes increases the risk of heart failure with preserved ejection fraction, suggesting a connection with obesity.
- Excess adiposity serves as a primary mediator between type 2 diabetes and heart failure, via inflammation and metabolic changes.
- Research indicates that interventions targeting adiposity may reduce heart failure risk more effectively than those focused solely on lowering blood glucose.
- Certain treatments, including glucagon-like peptide receptor agonists, show promise in improving heart health by addressing adipose tissue rather than just hyperglycemia.
Structured PICO
Does targeting adiposity rather than hyperglycemia reduce the risk or progression of HFpEF in patients with Type 2 diabetes?
P
Population
Patients with Type 2 diabetes and heart failure with preserved ejection fraction (HFpEF)
I
Intervention
Treatments directed toward adiposity (e.g., GLP-1 receptor agonists, SGLT2 inhibitors, bariatric surgery)
C
Comparator
Treatments directed toward hyperglycemia (e.g., insulin, sulfonylureas, DPP-4 inhibitors, thiazolidinediones)
O
Outcome
Risk or progression of HFpEF
Type 2 diabetes is a modifiable risk factor for HFpEF only when treatments target the associated excess adiposity rather than just hyperglycemia.
Cite This Study
Packer et al. (2025) conducted a review in Heart failure with a preserved ejection fraction (HFpEF) and Type 2 Diabetes. Adiposity-targeted treatments vs. Hyperglycemia-targeted treatments was evaluated. Diabetes-associated HFpEF is mediated primarily through excess adiposity, making it a modifiable risk factor when treatments target adiposity rather than hyperglycemia.